These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18187874)

  • 1. Association between baseline values of bone turnover markers and bone mineral density and their response to raloxifene treatment in Japanese postmenopausal women with osteoporosis.
    Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    Endocr J; 2008 Mar; 55(1):41-8. PubMed ID: 18187874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-month changes in bone turnover markers and bone mineral density response to raloxifene in Japanese postmenopausal women with osteoporosis.
    Majima T; Shimatsu A; Satoh N; Komatsu Y; Fukao A; Ninomiya K; Matsumura T; Nakao K
    J Bone Miner Metab; 2008; 26(2):178-84. PubMed ID: 18301975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of 1-year treatment with raloxifene on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis.
    Majima T; Komatsu Y; Shimatsu A; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    Endocr J; 2007 Dec; 54(6):855-62. PubMed ID: 17917307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
    Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
    Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
    Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis.
    Majima T; Komatsu Y; Shimatsu A; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    Endocr J; 2008 Mar; 55(1):127-34. PubMed ID: 18219181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
    Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
    Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
    Gorai I; Hattori S; Tanaka Y; Iwaoki Y
    J Bone Miner Metab; 2012 May; 30(3):349-58. PubMed ID: 22130786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.
    Tanaka M; Itoh K; Matsushita K; Matsushita K; Moriishi M; Kawanishi H; Fukagawa M
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():62-6. PubMed ID: 21595855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.
    Kendler DL; Palacios S; Cox DA; Stock J; Alam J; Dowsett SA; Zanchetta J
    Osteoporos Int; 2012 Mar; 23(3):1091-101. PubMed ID: 21374068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
    Downs RW; Moffett AM; Ghosh A; Cox DA; Dowsett SA; Harper K
    Osteoporos Int; 2010 Jul; 21(7):1215-26. PubMed ID: 19798460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
    Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy.
    Cosman F; Nieves JW; Zion M; Barbuto N; Lindsay R
    Osteoporos Int; 2008 Apr; 19(4):529-35. PubMed ID: 17929072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
    Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA
    Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.